Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Status:
Terminated
Trial end date:
2017-01-19
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies stereotactic body radiation therapy followed by combination
chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body
radiation therapy is a specialized radiation therapy that delivers one to five high doses of
radiation directly to the tumor and may kill more tumor cells and cause less damage to normal
tissue than conventional radiation. Drugs used in chemotherapy, such as carboplatin and
paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving stereotactic body radiation therapy, followed by
carboplatin, and paclitaxel albumin-stabilized nanoparticle formulation may kill more tumor
cells and result in a better and more durable response than conventional radiation and
chemotherapy. The purpose of this study is to test the safety of this approach prior to
larger studies.